One-Year Outcomes of Intravitreal Faricimab Injection in Treatment-Naïve Patients With Neovascular Age-Related Macular Degeneration

<b>Purpose:</b> To investigate the 1-year functional and morphologic outcomes of intravitreal (IVT) faricimab in treatment-naïve Japanese patients with neovascular age-related macular degeneration (nAMD). <b>Methods:</b> A retrospective study was performed to examine the outcomes of patients with nAMD who received IVT faricimab using a treat-and-extend regimen. The best-corrected visual acuity (BCVA), central foveal thickness (CFT), central choroidal thickness, dry macular achievement, and treatment intervals at 48 weeks were evaluated. Furthermore, the presence of polypoidal lesions at 48 weeks, as indicated by indocyanine green angiography, was investigated in patients with polypoidal choroidal vasculopathy (PCV). <b>Results:</b> This study included 48 Japanese treatment-naïve patients with nAMD assessed at 1 year of follow-up. The BCVA was significantly improved 1 year after initial treatment (<i>P</i> < .001). CFT and central choroidal thickness were also significantly decreased after 1 year (<i>P</i> < .001 and <i>P</i> < .001, respectively). Dry macula was achieved in 42 eyes (87.5%), and the mean (±SD) treatment interval at 12 months was 14.5 ± 4.4 weeks. The 1-year polyp regression rate was 76.9% (10/13 eyes). <b>Conclusions:</b> IVT faricimab was well tolerated and appeared to improve both functional and anatomic outcomes in Japanese patients with nAMD. In addition, a high rate of polyp regression was seen in patients with PCV.